# Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age

> **NCT00423046** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 1106 (actual)

## Conditions studied

- Infections, Papillomavirus
- Papillomavirus Vaccines

## Interventions

- **BIOLOGICAL:** GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM)
- **BIOLOGICAL:** Gardasil ® (Merck & Co. Inc)
- **BIOLOGICAL:** Placebo
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT00423046
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01-24
- **Primary completion:** 2008-03-07
- **Final completion:** 2012-05-14
- **Target enrollment:** 1106 (ACTUAL)
- **Last updated:** 2020-01-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00423046

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00423046, "Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00423046. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*